Details

Autor(en) / Beteiligte

• Maron, Barry J.
• McKenna, William J.
• Danielson, Gordon K.
• Kappenberger, Lukas J.
• Kuhn, Horst J.
• Seidman, Christine E.
• Shah, Pravin M.
• Spencer, William H.
• Spirito, Paolo
• Ten Cate, Folkert J.
• Wigle, E.Douglas
• Vogel, Robert A.
• Abrams, Jonathan
• Bates, Eric R.
• Brodie, Bruce R.
• Danias, Peter G.
• Gregoratos, Gabriel
• Hlatky, Mark A.
• Hochman, Judith S.
• Kaul, Sanjiv
• Lichtenberg, Robert C.
• Lindner, Jonathan R.
• O’rourke, Robert A.
• Pohost, Gerald M.
• Schofield, Richard S.
• Tracy, Cynthia M.
• Winters, William L.
• Klein, Werner W.
• Priori, Silvia G.
• Alonso-Garcia, Angeles
• Blomström-Lundqvist, Carina
• De Backer, Guy
• Deckers, Jaap
• Flather, Markus
• Hradec, Jaromir
• Oto, Ali
• Parkhomenko, Alexander
• Silber, Sigmund
• Torbicki, Adam

Titel

American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines

Ist Teil von

• Journal of the American College of Cardiology, 2003-11, Vol.42 (9), p.1687-1713

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2003

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• The panel focused largely on the management of this complex disease and derived prudent, practical, and contemporary treatment strategies for the many subgroups of patients comprising the broad HCM disease spectrum. Because of the relatively low prevalence of HCM in general cardiologic practice (50), its diverse presentation, and mechanisms of death and disability and skewed patterns of patient referral (7,11,13,36-38,42,51-59), the level of evidence governing management decisions for drugs or devices has often been derived from non-randomized and retrospective investigations. Large-scale controlled and randomized study designs, such as those that have provided important answers regarding the management of coronary artery disease (CAD) and congestive heart failure (60-62), have generally not been available in HCM as a result of these factors. [...]treatment strategies have necessarily evolved based on available data that have frequently been observational in design, sometimes obtained in relatively small patient groups, or derived from the accumulated clinical experience of individual investigators, and reasonable inferences drawn from other cardiac diseases.